Clearly, the increase in life expectancy has triggered a shift in the leading causes of disease and death emphasizing the emergence of chronic and degenerative diseases, and the need for developing innovative neurotechnologies to address disabilities and health care costs (Global Health & Aging, 2011).
About 10M people worldwide are living with Parkinson’s disease (PD) including 1M Americans (Parkinson’s disease statistics, 2013).
Stroke is also a leading cause of serious long-term disability along with spinal cord injury.
The combined direct and indirect costs of these three disabilities alone are in excess of $100B annually (Spinal Cord Injury Facts and Figures at a Glance, 2009).
In addition, there are 1.8M+ Americans living with limb loss (Amputee statistics, 2009). The Centers for Disease Control and Prevention estimate that by developing novel therapies and technologies for preventing new injuries, the US can save as much as $400B on future direct and indirect lifetime costs (CDC, 2010).
Therefore, it is imperative to engineer truly effective human-machine systems, tools, and devices to improve care and reduce the financial burden of disability due to chronic and degenerative diseases.
In 2010, there were approximately 39 million people in the world living with blindness (“Global estimates of visual impairment: 2010,” Br. J. Ophthalmol.). Damage to various locations along the visual track can cause a variety of visual deficits – retinitis pigmentosa (RP) involves damage to the photoreceptors of the retina, while the optic nerve is damaged by glaucoma. Once it has occurred blindness cannot be treated pharmaceutically and there is only one commercially available vision-restoring neural prosthetic device.